"RIV/00216208:11120/08:00002197!RIV11-MSM-11120___" . . "Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial" . . "Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial" . "128" . "377149" . "Hahn, Ale\u0161" . "Meniere's disease; betahistine-dihydrochloride; attacks of vertigo; long-term treatment"@en . "Acta Oto-Laryngologica" . "9"^^ . "NO - Norsk\u00E9 kr\u00E1lovstv\u00ED" . "Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial"@en . . "5"^^ . . . . . "RIV/00216208:11120/08:00002197" . "Despite the considerable limitations of an open, non-masked trial, particularly in Menire's disease (MD), a higher dosage of betahistine-dihydrochloride and a long-term treatment seems to be more effective than a low dosage and short-term treatment. Objective. To evaluate the prophylactic effects of a low versus high dosage long-term treatment with betahistine-dihydrochloride on the number of attacks in MD. Patients and methods. We performed an open, non-masked trial, in which patients with MD received either a low dosage of betahistine-dihydrochloride (16 or 24 mg tid) or a higher dosage of 48 mg tid for at least 12 months. The outcome measure was the number of attacks per month during a 3-month period. Non-parametric tests and a random effects model were used for statistical analysis. Results. A total of 112 patients were included in the analysis: 50 received betahistine-dihydrochloride in a low dosage (16 mg tid, n=21, 24 mg, n=29) and 62 received 48 mg tid. Follow-up examination every 3 month" . . . "1"^^ . "Despite the considerable limitations of an open, non-masked trial, particularly in Menire's disease (MD), a higher dosage of betahistine-dihydrochloride and a long-term treatment seems to be more effective than a low dosage and short-term treatment. Objective. To evaluate the prophylactic effects of a low versus high dosage long-term treatment with betahistine-dihydrochloride on the number of attacks in MD. Patients and methods. We performed an open, non-masked trial, in which patients with MD received either a low dosage of betahistine-dihydrochloride (16 or 24 mg tid) or a higher dosage of 48 mg tid for at least 12 months. The outcome measure was the number of attacks per month during a 3-month period. Non-parametric tests and a random effects model were used for statistical analysis. Results. A total of 112 patients were included in the analysis: 50 received betahistine-dihydrochloride in a low dosage (16 mg tid, n=21, 24 mg, n=29) and 62 received 48 mg tid. Follow-up examination every 3 month"@en . "[463A14239FA0]" . . . . "11120" . "Long-term prophylactic treatment of attacks of vertigo in Menire's disease - comparison of a high with a low dosage of betahistine in an open trial"@en . "5" . "0001-6489" . "N" . . . "000255042200005" . .